Part 8/10:
The discussion turned towards the evolving landscape of mergers and acquisitions (M&A) in the biotech and pharma sectors. Companies are increasingly looking for opportunities beyond standalone products, focusing on integrating platforms or technologies that can yield future innovations. This trend marks a significant shift in acquisition strategies as firms aim to bolster their R&D capabilities while mitigating risks associated with drug development.